MassBio and Health Advances Launch Effort to Draft 2020 Strategic Plan
Report will analyze opportunities and threats to MA cluster, make recommendations to ensure future growth of life sciences in Commonwealth
MassBio has launched Impact 2020, an effort to prepare a strategic plan to secure Massachusetts’ status as a life sciences industry supercluster into the next decade.
The report will be developed by Weston-based Health Advances, a leading life sciences-focused strategy consulting firm, and include insights garnered from more than 100 industry stakeholder interviews, online discussions hosted by industry stars and facilitated by the report team, and a series of discussion-based events through next spring.
An Advisory Board representing the broad reach of our industry will provide thought-leadership and will guide the report’s focus. Members include:
· Josh Boger, PhD – Former CEO, Vertex Pharmaceuticals
· Bruce Booth, PhD – Partner, Atlas Venture
· Katrine Bosley – Former CEO, Avila Therapeutics
· Michelle Dipp, MD, PhD – CEO and Co-Founder, OvaScience
· Todd Golub, MD – Founder, CSO and Director, Cancer Program, Broad Institute
· Gary Gottlieb, MD – President and CEO, Partners HealthCare
· Nick Leschly – President & CEO, bluebird bio
· Terry McGuire – Co-Founder/General Partner, Polaris Partners
· Michael Rosenblatt – Executive Vice President & CMO, Merck
· Vicki L. Sato, PhD – Professor of Management Practice, Harvard Business School
· Eric H. Schultz – President and CEO, Harvard Pilgrim Health Care
· Josef H. von Rickenbach – Chairman and CEO, PAREXEL International
“We are determined to engage the broadest reaches of our membership and industry in laying out a vision for life sciences in the next several years,” said MassBio President and CEO Robert K. Coughlin. “Impact 2020 will set a path forward for the industry and make recommendations for our partners in government and academia to ensure Massachusetts’ position as an industry leader.”
“We are excited to partner with MassBio and our local industry colleagues on this important endeavor,” said Skip Irving, Partner and Managing Director at Health Advances. “Massachusetts has many strengths that have served our industry well but we cannot rest on our laurels. Our industry is constantly challenged to prove that it is delivering valuable products for patients so we must constantly push ourselves to cultivate an innovative and productive environment.”
Impact 2020 will outline a clearly articulated roadmap for the continued growth of the life sciences industry as economics, business models, policies and healthcare practices continue to shift through the next several years. Health Advances will work with MassBio to create the strategic plan using dozens of stakeholder interviews and analysis of market factors, business trends and competitive clusters.
The strategic plan will assess the critical events, trends, policies and discoveries that will impact the life sciences sector through 2020 and make recommendations to ensure the industry thrives in Massachusetts for generations to come. Our goal is to incorporate the views and interests of all industry stakeholders: life sciences and biopharma companies, government, academia, investors, providers and patients.
MassBio selected the Health Advances team specifically for their vast experience in the industry through working with hundreds of healthcare companies and investor groups and their stakeholder perspective approach to all projects. The report’s development phase will run from August 2013 through February 2014 and will be overseen by a MassBio Board Steering Committee and Advisory Board.
Past MassBio strategic reports have led to new programs and initiatives that have proven to bolster the industry. The state’s $1 billion Life Sciences Initiative, and the investments and programs that followed, were the result of recommendations and advocacy undertaken following MassBio’s 2010 Report. The popular Pharma Days business development events and MassCONNECT mentoring program were the result of recommendations made in MassBio’s 2015 Report.